A single-center, early-phase clinical trial showed impressive therapeutic efficacy of anti-CD7 CAR-T cells for relapsed and/or refractory T-ALL (ChiCTR2000034762) [52]. Here, CD7 is linked to acute lymphoblastic leukemia.